Niclosamide
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Niclosamide
UNSPSC Description:
Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells[2][3][5].Target Antigen:
Antibiotic; Parasite; STATType:
Reference compoundRelated Pathways:
Anti-infection;JAK/STAT Signaling;Stem Cell/WntApplications:
COVID-19-immunoregulationField of Research:
Infection; CancerAssay Protocol:
https://www.medchemexpress.com/Niclosamide.htmlPurity:
99.90Solubility:
DMF : 5 mg/mL (ultrasonic)|DMSO : 4.55 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)Smiles:
O=C(NC1=CC=C([N+]([O-])=O)C=C1Cl)C2=CC(Cl)=CC=C2OMolecular Weight:
327.12References & Citations:
[1]P Andrews, et al. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19(2):245-95.|[2]Wei Chen, et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89-96.|[3]Kei Satoh, et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016 Jul 15;22(14):3458-66.|[4]Xiaomei Ren, et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett. 2010 Sep 7;1(9):454-9.|[5]Chang-Jer Wu, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Clinical Information:
LaunchedCAS Number:
50-65-7
